Ozempic provide will proceed to be restricted till the tip of 2025, based on the most recent recommendation from Novo Nordisk, Ozempic’s provider.
The Therapeutic Items Administration (TGA) stated Novo Nordisk has suggested that it’s persevering with to extend manufacturing capability, however it will take time to construct provide ranges to satisfy world and Australian demand.
The TGA stated the semaglutide product is accredited for the administration of sort 2 diabetes not adequately managed by different medicines, together with eating regimen and train. A separate semaglutide product, Wegovy, is accredited to assist with continual weight administration.
Diabetes Australia understands the numerous considerations of Australians dwelling with sort 2 diabetes in regards to the ongoing Ozempic scarcity and can proceed to advocate for prioritised entry for folks dwelling with diabetes.
Diabetes Australia has advocated for the TGA to research the shortages of quite a lot of diabetes-related medicines and merchandise lately and redouble efforts to make sure Australians will be assured that provide chains are enough to satisfy their wants.
The TGA has requested well being professionals to:
- contemplate the continued scarcity when prescribing Ozempic, inform sufferers that provide is anticipated to be restricted in 2025, and talk about different therapies when sufferers are unable to entry the drugs.
- prescribe and provide each Ozempic and Wegovy based on their accredited indications.
Details about the Ozempic scarcity is offered from the TGA web site.
